Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Atheroscler Rep ; 25(11): 819-827, 2023 11.
Article in English | MEDLINE | ID: mdl-37768411

ABSTRACT

PURPOSE OF THE REVIEW: Systemic lupus erythematosus (SLE) patients are at increased risk of cardiovascular disease (CVD) compared to the general population, despite most patients being young females, who are not classically considered to be at high risk for cardiovascular disease using traditional risk assessment tools. The purpose of this review is to discuss the pathophysiology of atherosclerosis in SLE and raise awareness of the relationship between SLE and CVD. RECENT FINDINGS: The increased risk of CVD in SLE patients is multifactorial, due to proatherogenic lipid profiles, immune dysregulation and inflammation, side effects of lupus treatment, and microvascular dysfunction. Conventional CV risk models often underperform in the identification of SLE patients at high risk of atherosclerosis. The use of non-invasive imaging serves as a strategy to identify patients with evidence of subclinical CVD and in the evaluation of symptomatic patients. Identification of subclinical atherosclerosis allows for aggressive management of CV risk factors. SLE patients experience an increased risk of atherosclerotic CVD, which is not solely explained by traditional CV risk factors. It is imperative that clinicians are aware of this association to implement prompt detection and treatment of atherosclerotic CVD in SLE patients.


Subject(s)
Atherosclerosis , Cardiovascular Diseases , Lupus Erythematosus, Systemic , Female , Humans , Cardiovascular Diseases/etiology , Atherosclerosis/etiology , Atherosclerosis/epidemiology , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/epidemiology , Risk Factors , Inflammation/complications
2.
J Am Coll Cardiol ; 81(14): 1368-1385, 2023 04 11.
Article in English | MEDLINE | ID: mdl-37019584

ABSTRACT

Social determinants of health (SDOH) are the social conditions in which people are born, live, and work. SDOH offers a more inclusive view of how environment, geographic location, neighborhoods, access to health care, nutrition, socioeconomics, and so on are critical in cardiovascular morbidity and mortality. SDOH will continue to increase in relevance and integration of patient management, thus, applying the information herein to clinical and health systems will become increasingly commonplace. This state-of-the-art review covers the 5 domains of SDOH, including economic stability, education, health care access and quality, social and community context, and neighborhood and built environment. Recognizing and addressing SDOH is an important step toward achieving equity in cardiovascular care. We discuss each SDOH within the context of cardiovascular disease, how they can be assessed by clinicians and within health care systems, and key strategies for clinicians and health care systems to address these SDOH. Summaries of these tools and key strategies are provided.


Subject(s)
Health Services Accessibility , Social Determinants of Health , Humans , Socioeconomic Factors , Residence Characteristics
4.
Am Heart J Plus ; 13: 100109, 2022 Jan.
Article in English | MEDLINE | ID: mdl-38560055

ABSTRACT

Cardiovascular disease (CVD) is the leading cause of death in women, with underrepresented minority (URM) women experiencing the highest mortality rate. For decades, there has been an underrepresentation of women in CVD trials. Although more recent studies have increased the number of women enrolled in these trials, systematic reviews have demonstrated that this enrollment is still low. The National Institute of Health along with other agencies have boosted their efforts to increase enrollment of women and URM populations in CVD trials. Despite these efforts, there still remains a gap. This paper reviews the magnitude, implications and causes of the underrepresentation of women in CVD trials. A proposed multifaceted approach to solving this issue is also outlined in this commentary. Hopefully, implementation of these proposed solutions may facilitate the increase of women, including URM women, enrolled in CVD trials. It is anticipated that this will improve CVD outcomes in these patients.

5.
J Innov Card Rhythm Manag ; 11(2): 3986-3988, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32368370

ABSTRACT

We describe the case of a patient who received cardiac resynchronization pacemaker therapy (CRT-P) incorporating bridge protection via a wearable cardioverter-defibrillator (WCD) while awaiting final evaluation for permanent placement of an implantable CRT device with defibrillation capabilities. In an attempt to mitigate symptoms of heart failure, reprogramming of the CRT-P with a V-V offset caused an unusual interaction and alarm from the WCD. This case highlights a unique interaction not previously reported and is clinically relevant to patients awaiting final evaluation for implantable defibrillator system placement.

SELECTION OF CITATIONS
SEARCH DETAIL
...